Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the ...

Elon Musk’s X reacts to reports of potential penalties from the E.U. Judge orders US to bring Kilmar Abrego Garcia back from ...

"The initiation of patient dosing in our CLEAR-AD1 Phase 2b clinical trial is another significant milestone for Alphyn, as we strive to bring to market our single comprehensive treatment for ...